Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Ficlatuzumab · AV-299, SCH 900105

Monoclonal antibody · Antagonist of hepatocyte growth factor (HGF) · developed by AVEO Pharmaceuticals

Phase 2/3 Most advanced trial
1 Registered trials

What is Ficlatuzumab?

Ficlatuzumab is a humanized monoclonal antibody that binds hepatocyte growth factor (HGF), preventing HGF activation of its receptor c-Met. This blocks HGF/c-Met signaling, which may induce cell death in c-Met-expressing tumor cells. It is studied in acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AV-299, SCH 900105
Drug type
Monoclonal antibody
Targets
hepatocyte growth factor (HGF), c-Met (MET) (secondary target)
Mechanism
Antagonist of hepatocyte growth factor (HGF)
Pathways
HGF/c-Met signaling, angiogenesis
Therapy area
Hematology, Oncology
Developer
AVEO Pharmaceuticals, Inc.
In trials of
SNDX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
77E89833TG

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03013998 Phase 2/3 Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Recruiting SNDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.